Enlivex Announces World's First Prediction Markets Token Rain (RAIN) Treasury Strategy
RAIN will serve as the company's primary treasury reserve asset.
Harnessing the natural healing power of macrophages to treat inflammatory diseases.
Enlivex’s proprietary off-the-shelf cell therapy platform Allocetra™ with its novel therapeutic mechanism has the potential to redefine the way inflammatory diseases are treated.
Allocetra™ offers off-the-shelf and easy to use, flexible administration options, including systemic intravenous infusion or targeted local injections.
Over 250 patients have been safely treated with Allocetra™ in various clinical trials, more than 120 of which administered intra-articularly, with no reported drug related serious adverse events.
Enlivex is evaluating Allocetra™ for the treatment of multiple indications including acute inflammatory diseases such as sepsis and chronic inflammatory diseases like osteoarthritis.
-
clinically tested
-
no serious adverse events
-
cost-effective cell therapy
If you would like to learn more about Enlivex, Allocetra™ or are interested in participating in one of our clinical trials, please contact us.
FOR MORE INFORMATION